Igf::ot::igf Sbir Phase I Topic 350 Quantification of Redox

Period of Performance: 09/19/2016 - 06/18/2017

$225K

Phase 2 SBIR

Recipient Firm

Dynupol, Inc.
Newton, MA 02458
Principal Investigator

Abstract

Current clinical magnetic resonance metabolic imaging techniques are severely hindered by poor sensitivity. Dynamic nuclear polarization solves this problem by transferring polarization from the highly-polarized electron spins of a polarization agent to the nuclear spins of the target MRI probe. The metabolite dehydroascorbic acid (DHA) has been shown to be an excellent hyperpolarized probe of cellular redox capacity providing a measure of the cells ability to quench reactive oxygen species (ROS). Pre-clinical studies have demonstrated hyperpolarized DHA's ability to measure increased reducing capacity in cancer and diabetes-induced renal oxidative stress and their response to therapy, and it?s anticipated to have broad applicability to a variety of diseases. With the successful clinical translation of 13C MRI of hyper polarized [1-13C] pyruvate, the use of HP [1-13C]DHA in patients is being actively pursued. However, the spatiotemporal resolution of HP [1-13C]DHA is severely hampered by the relatively poor polarization that is being obtained using the current trityl-based polarization radicals. Additionally, broad use of HP DHA is limited by the high cost of the trityl radicals. A Phase I effort will focus on increasing DHA?s polarization by 2-fold with Dynupol?s polarization agents, enabling higher resolution and sensitivity in cellular-redox imaging of a variety of diseases.